Actively Recruiting
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Led by Geneplus-Beijing Co. Ltd. · Updated on 2024-07-18
250
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
G
Geneplus-Beijing Co. Ltd.
Lead Sponsor
S
Shanghai Chest Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.
CONDITIONS
Official Title
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provision of informed consent
- Newly diagnosed and histologically or cytologically confirmed stage IIIB-IV lung adenocarcinoma or squamous cell carcinoma
- No EGFR mutation detected in tissue and ctDNA
- Receiving immune checkpoint inhibitors as first line therapy
- ECOG performance status between 0 and 2 with expected survival over 6 months
- Willing to follow study protocols and allow use of data for research and product development
You will not qualify if you...
- Presence of other primary cancers
- Symptomatic brain metastasis or related complications, or cognitive disorders
- Failure in quality control of either plasma or tissue samples
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Chest Hospital
Shanghai, China
Actively Recruiting
Research Team
R
Rongrong Chen, MD, PhD
CONTACT
L
Lianpeng Chang, MS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here